PNC-27 vs IGF-1 LR3
Side-by-side comparison of key properties, dosing, and research.
- Summary
- PNC-27 is a synthetic peptide derived from the p53 tumor suppressor protein, containing both an HDM2-binding domain and a transmembrane penetratin sequence. It selectively kills cancer cells by binding MDM2/HDM2 overexpressed on the plasma membrane of malignant cells, inducing membranolysis without harming normal cells.
- IGF-1 LR3 is a synthetic analog of Insulin-like Growth Factor-1 with an extended half-life. It is one of the most potent anabolic peptides available, directly stimulating muscle cell hyperplasia and hypertrophy, and is the downstream mediator of many of GH's anabolic effects.
- Half-Life
- Not well established; estimated minutes to hours
- 20–30 hours
- Admin Route
- Intravenous (research), Intraperitoneal (research)
- SubQ, IM
- Research
- —
- —
- Typical Dose
- Not established for humans; research doses vary by cell line and model
- 40–80 mcg
- Frequency
- Not established for human use
- Once daily or split twice daily
- Key Benefits
- Selective cytotoxicity against cancer cells overexpressing HDM2/MDM2
- Spares normal cells lacking surface HDM2 expression
- Membranolytic mechanism bypasses intracellular resistance pathways
- Demonstrated activity against breast, pancreatic, leukemia, and melanoma cell lines
- Potential for combination with conventional chemotherapy
- Novel non-genotoxic anticancer mechanism
- Direct muscle hypertrophy via IGF-1R stimulation
- Muscle hyperplasia (new fiber formation) — unique among peptides
- Rapid gains in lean muscle mass
- Accelerated recovery from training and injury
- Increased nutrient uptake by muscle cells
- Fat oxidation enhancement
- Bone density improvement
- Cartilage and connective tissue repair
- Side Effects
- Limited human clinical data; largely in vitro and animal studies
- Potential immunogenic reactions (foreign peptide)
- Systemic toxicity at high doses not well characterized
- Unknown interactions with current chemotherapy agents
- Hypoglycemia (significant risk — insulin-like activity)
- Acromegaly-like effects with excessive long-term use
- Jaw and hand swelling
- Organ hypertrophy with extreme doses
- +2 more
- Stacks With
- —
- —